/ CompletedNot Applicable Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
The primary objective of the study is to determine the estimated clinical specificity of the AAD Plus. A secondary objective is to determine the estimated sensitivity of the AAD Plus as 10% of the study subject samples will be contrived to be positive.
/ CompletedNot Applicable Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.
100 Clinical Results associated with Fast-Track Drugs & Biologics, L L C
0 Patents (Medical) associated with Fast-Track Drugs & Biologics, L L C
05 Oct 2021·Clinical Infectious DiseasesQ1 · MEDICINE
Miltefosine Treatment of Cutaneous Leishmaniasis
Q1 · MEDICINE
Communications
Author: Berman, Jonathan D ; Soto, Jaime A
18 May 2021·Clinical Infectious DiseasesQ1 · MEDICINE
Q1 · MEDICINE
Communications
Author: Berman, Jonathan D
05 May 2021·The American Journal of Tropical Medicine and HygieneQ4 · MEDICINE
Case Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine
Q4 · MEDICINE
Author: Berman, Jonathan D. ; Soto, Jaime A. ; Méndez, María Isabel
ABSTRACTWe present case reports of two patients treated with miltefosine for mucocutaneous leishmaniasis whose gastrointestinal symptoms were initially diagnosed as a drug reaction and only later recognized as due to COVID-19. Gastrointestinal symptoms of COVID-19 are unusual, whereas gastrointestinal adverse drug reactions are very common. These reports exemplify that this infrequent presentation of COVID-19 is likely to be ascribed to a more common etiology such as a gastrointestinal drug reaction.
100 Deals associated with Fast-Track Drugs & Biologics, L L C
100 Translational Medicine associated with Fast-Track Drugs & Biologics, L L C